

# Strategies for Combating Lyme Disease: Preventive Measures and Vaccine Development



By Paul Glenn | June 3, 2024

Estimated reading time: 5 minutes

## Unveiling the Intricacies of Lyme Disease and Its Vector

Lyme disease, a tick-borne infection caused by *Borrelia burgdorferi* bacteria, is transmitted by the bite of an infected black-legged tick or deer tick (*Ixodes scapularis* and *Ixodes pacificus*) [1] [2] [3]. These ticks are prevalent in wooded or grassy environments and undergo a life cycle comprising four stages: egg, larva, nymph, and adult [4]. Lyme disease manifests a variety of symptoms affecting multiple bodily systems, potentially leading to severe complications if left untreated [5]. To enhance protection against this ailment, it is imperative to delve into preventive strategies and the future trajectory of vaccination.



*Ixodes scapularis* [6]



*Ixodes pacificus* [7]

## Lyme Disease Overview: A Global Health Concern

Initially identified in Lyme, Connecticut, Lyme disease has now proliferated across North America and various regions worldwide [8] [9]. Black-legged ticks necessitate three blood meals to complete their life cycle, with larval and nymph stages primarily feeding on small mammals [10] [11]. Common symptoms of Lyme disease encompass fatigue, fever, headache, muscle and joint pains, swollen lymph nodes, and a characteristic "bull's-eye" rash known as erythema migrans.

Untreated cases can escalate to severe complications impacting the joints, heart, and nervous system [5] [12]. Timely diagnosis and treatment are pivotal for a successful recovery. Even post-recovery, symptoms may persist in the form of Post-Treatment Lyme Disease Syndrome (PTLDS), leading to fatigue, joint and muscle aches, and cognitive impairments, which diminish quality of life and cause emotional distress.

### **Pioneering Efforts in Lyme Vaccination**

Despite the substantial impact of Lyme disease, licensed vaccines for preventive purposes are currently unavailable. Nevertheless, promising advancements in the field suggest the potential emergence of a vaccine in the forthcoming tick season. Two notable preventive options include the VLA-15 vaccine and Lyme PrEP.


**VLA-15 Vaccine:** Developed by Valneva SE, the VLA-15 vaccine is aimed at eliciting an immune response against *Borrelia burgdorferi* [13]. This vaccine, crafted using recombinant technology, comprises six purified proteins derived from the bacterium [13]. Preliminary clinical trials have exhibited promising safety and immunogenicity profiles, with plans for further evaluation and potential licensure [13].

**Lyme PrEP:** While not a traditional vaccine, Lyme PrEP (Pre-Exposure Prophylaxis) offers an alternative preventive approach through an injectable solution. Lyme PrEP contains proteins that bind to the *B. burgdorferi* bacterium upon a tick bite, thwarting infection [14]. It confers temporary protection against Lyme disease and is primarily recommended for individuals frequently exposed to tick-infested locales during high-risk seasons, such as fieldworkers or hikers [14]. Although efficacy data is limited, initial studies indicate potential benefits for at-risk individuals [14].

### **Mitigating Vaccine Apprehensions: Evaluating Risks and Benefits**

It is common for individuals to be wary about vaccination due to concerns about adverse effects or safety. However, the advantages of vaccination in averting severe illnesses significantly outweigh the associated risks, particularly in regions with prevalent tick populations and high disease incidence.

**Risk-Benefit Analysis:** When contemplating vaccination, it is essential to weigh the risks linked to potential adverse reactions against the protective benefits conferred against the disease. In the context of Lyme disease, the likelihood of contracting the ailment due to a tick bite is notably higher in regions with elevated infection rates [15]. By embracing preventive measures like vaccines or Lyme PrEP, individuals can minimize the risk of severe complications associated with Lyme disease.



**Addressing Reactions:** While vaccines are generally safe, some individuals may encounter mild side effects such as injection site discomfort, fatigue, or low-grade fever [16]. Severe reactions are rare; nevertheless, individuals with known allergies to vaccine components should seek counsel from healthcare providers before vaccination [17]. By communicating any potential allergies or sensitivities with healthcare providers, individuals can mitigate risks associated with adverse reactions [18].

### **Additional Preventive Methods for Ticks**

Beyond vaccines and Lyme PrEP, several preventive measures are recommended.

**Tick Avoidance:** Minimize direct contact with ticks and their habitats by evading wooded and grassy locales, as well as leaf litter [19]. When venturing into tick-prone areas, apply insect repellents that contain a minimum of 20% DEET on yourself and accompanying pets, and wear long-sleeved shirts, pants, and closed-toe shoes [20].

**Tick Checks:** Conduct regular comprehensive tick inspections following outdoor activities, focusing on clothing, equipment, and pets. Ticks frequently latch onto attire, hence tumble drying clothes at high heat for 10 minutes can aid in eradicating any present ticks [21] [22].

**Landscaping:** Establish a tick-safe perimeter around residences by maintaining trimmed lawns, clearing leaf litter, and introducing wood chips or gravel barriers between wooded zones and yards [23].

Lyme disease, propagated through black-legged tick bites, stands as a significant public health menace. While licensed vaccines are currently unavailable, promising initiatives like the VLA-15 vaccine and Lyme PrEP offer hope for enhanced prevention in the near future. By addressing vaccine-related concerns and promoting awareness of preventive strategies, we can safeguard individuals and communities against the repercussions of Lyme disease.

## References

1. Eisen, R.J., et al., *A spatially-explicit model of acarological risk of exposure to Borrelia burgdorferi-infected Ixodes pacificus nymphs in northwestern California based on woodland type, temperature, and water vapor*. Ticks Tick Borne Dis, 2010. **1**(1): p. 35-43.
2. Fischhoff, I.R., F. Keesing, and R.S. Ostfeld, *Risk Factors for Bites and Diseases Associated With Black-Legged Ticks: A Meta-Analysis*. Am J Epidemiol, 2019. **188**(9): p. 1742-1750.
3. Tokarz, R., et al., *Microbiome analysis of Ixodes scapularis ticks from New York and Connecticut*. Ticks and Tick-borne Diseases, 2019. **10**(4): p. 894-900.
4. LoGiudice, K., et al., *The ecology of infectious disease: effects of host diversity and community composition on Lyme disease risk*. Proc Natl Acad Sci U S A, 2003. **100**(2): p. 567-71.
5. Bacon, R.M., K.J. Kugeler, and P.S. Mead, *Surveillance for Lyme disease--United States, 1992-2006*. MMWR Surveill Summ, 2008. **57**(10): p. 1-9.
6. Alpert, G. *Blacklegged tick (Ixodes scapularis)*. n.d.; Available from: <https://www.forestryimages.org/browse/detail.cfm?imgnum=5380287Forestry> Images.
7. Loarie, G. *Western Blacklegged tick (Ixodes pacificus)*. n.d.; Available from: <https://www.flickr.com/photos/loarie/16748122297Flickr>.
8. Kugeler, K.J., et al., *Geographic Distribution and Expansion of Human Lyme Disease, United States*. Emerg Infect Dis, 2015. **21**(8): p. 1455-7.
9. Stone, B.L., Y. Tourand, and C.A. Brissette, *Brave New Worlds: The Expanding Universe of Lyme Disease*. Vector Borne Zoonotic Dis, 2017. **17**(9): p. 619-629.
10. Cadenas, F.M., et al., *Identification of Host Bloodmeal Source and Borrelia burgdorferi Sensu Lato in Field-Collected Ixodes ricinus Ticks in Chaumont (Switzerland)*. Journal of Medical Entomology, 2007. **44**(6): p. 1109-1117.
11. Schotthoefer, A. and H. Frost, *Ecology and Epidemiology of Lyme Borreliosis*. Clinics in Laboratory Medicine, 2015. **35**.
12. Fülöp, B. and G. Poggensee, *Epidemiological situation of Lyme borreliosis in Germany: Surveillance data from six Eastern German States, 2002 to 2006*. Parasitology Research, 2008. **103**(1): p. 117-120.
13. Hajdusek, O. and J. Perner, *VLA15, a new global Lyme disease vaccine undergoes clinical trials*. The Lancet Infectious Diseases, 2023. **23**(10): p. 1105-1106.
14. Wang, Y., et al., *Pre-exposure Prophylaxis With OspA-Specific Human Monoclonal Antibodies Protects Mice Against Tick Transmission of Lyme Disease Spirochetes*. The Journal of Infectious Diseases, 2016. **214**(2): p. 205-211.
15. Canada, P.H.A.o. *Lyme disease: Monitoring*. n.d.;
16. Geoghegan, S., K.P. O'Callaghan, and P.A. Offit, *Vaccine Safety: Myths and Misinformation*. Front Microbiol, 2020. **11**: p. 372.
17. McNeil, M.M., et al., *Risk of anaphylaxis after vaccination in children and adults*. J Allergy Clin Immunol, 2016. **137**(3): p. 868-78.
18. Olson, O., C. Berry, and N. Kumar, *Addressing Parental Vaccine Hesitancy towards Childhood Vaccines in the United States: A Systematic Literature Review of Communication Interventions and Strategies*. Vaccines (Basel), 2020. **8**(4).

19. Jordan, A.J. and T.L. Schulze, *Artificial Accumulation of Leaf Litter in Forest Edges on Residential Properties via Leaf Blowing Is Associated with Increased Numbers of Host-Seeking Ixodes scapularis (Acari: Ixodidae) Nymphs* Journal of Medical Entomology, 2020. **57**(4): p. 1193-1198.
20. Le Mauff, A., et al., *Effect of the combination of DEET and flupyradifurone on the tick Ixodes ricinus: Repellency bioassay and pharmacological characterization using microtransplantation of synganglion membranes*. Ticks and Tick-borne Diseases, 2023. **14**(1): p. 102079.
21. Prevention, C.f.D.C.a. *Preventing tick bites on people*. 2020; Available from: [https://www.cdc.gov/ticks/avoid/on\\_people.html](https://www.cdc.gov/ticks/avoid/on_people.html)
22. Nelson, C.A., et al., *The heat is on: Killing blacklegged ticks in residential washers and dryers to prevent tickborne diseases*. Ticks and Tick-borne Diseases, 2016. **7**(5): p. 958-963.
23. Ho, B.M., et al., *Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Management of Tick-Borne Illness in the United States*. Wilderness and Environmental Medicine, 2021. **32**(4): p. 474-494.